India Glycols Limited — PPTs, 14-08-2026: Investor Presentation

IGL had a robust Q1FY27. Consolidated Net Revenue rose 8.6% YoY to ₹1,130 Cr, EBITDA jumped 12.5% to ₹170 Cr, and PAT soared 32.2% to ₹97 Cr. Ennature Biopharma led growth (+65% revenue), followed by Chemicals (+21%) and Potable Spirits (+5%). Biofuel revenue dipped but EBIT improved.

The NCLT-approved demerger is a game-changer, creating three focused entities: India Glycols (Chemicals), IGL Spirits, & Ennature Bio Pharma. This strategic move aims to unlock shareholder value & improve operational focus. Growth plans include premiumization, new market entries, and backward integration.

Recent launches include new Vodka, Brandy, & Rum in Kerala, with a "Jamun Flavour" liquor planned for Uttarakhand. Nicotine processing capacity expanded. Finance costs significantly reduced.

Management projects strong FY27 for all entities: IGL Spirits eyes over ₹500 Cr EBITDA (targeting ₹1,000 Cr in 4-5 years, debt-free by FY28). India Glycols (Chemicals) aims for over ₹200 Cr EBITDA (₹400 Cr in 4-5 years). Ennature Biopharma expects over ₹50 Cr EBITDA (₹130-150 Cr in 4-5 years). Debt reduction and efficiency remain key.